Lord Abbett & CO. LLC Sells 108,079 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Lord Abbett & CO. LLC lowered its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 27.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 284,159 shares of the company’s stock after selling 108,079 shares during the quarter. Lord Abbett & CO. LLC’s holdings in Krystal Biotech were worth $51,726,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of KRYS. Summit Trail Advisors LLC bought a new stake in shares of Krystal Biotech during the third quarter worth about $1,893,000. Swiss National Bank boosted its position in shares of Krystal Biotech by 8.0% during the third quarter. Swiss National Bank now owns 39,100 shares of the company’s stock valued at $7,117,000 after buying an additional 2,900 shares during the last quarter. Sei Investments Co. grew its holdings in Krystal Biotech by 18.9% during the second quarter. Sei Investments Co. now owns 40,115 shares of the company’s stock worth $7,367,000 after buying an additional 6,363 shares in the last quarter. Shaker Investments LLC OH purchased a new stake in Krystal Biotech in the 3rd quarter valued at $532,000. Finally, Citigroup Inc. lifted its stake in Krystal Biotech by 65.4% during the 3rd quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock valued at $6,386,000 after acquiring an additional 13,874 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 14.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Stifel Nicolaus upped their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Chardan Capital reaffirmed a “buy” rating and issued a $212.00 target price on shares of Krystal Biotech in a report on Thursday. Finally, Citigroup lifted their price target on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $206.67.

Krystal Biotech Stock Down 5.6 %

Shares of KRYS stock opened at $163.64 on Friday. Krystal Biotech, Inc. has a 12-month low of $107.50 and a 12-month high of $219.34. The company has a 50 day moving average of $181.27 and a 200-day moving average of $185.06. The firm has a market cap of $4.71 billion, a P/E ratio of 92.45 and a beta of 0.80.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company’s revenue was up 879.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.67) earnings per share. As a group, equities analysts expect that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).